Form 4: Genmab Boosts Merus Stake to 72.8M Shares in Tender Offer

Genmab A/S, through its subsidiary, increased its beneficial ownership in Merus N.V. to over 72.8 million common shares following recent acquisitions as part of a tender offer.

Summary

• Genmab A/S (Parent) and its wholly-owned subsidiary, Genmab Holding II B.V. (Purchaser), reported additional acquisitions of Merus N.V. common shares.
• The acquisitions are part of a tender offer initiated following a transaction agreement entered into on September 29, 2025.
• On December 12, 2025, the Purchaser accepted 71,463,077 common shares, representing approximately 94.2% of Merus's outstanding shares, at a cash payment of $97.00 per share.
• During a subsequent offering period, the Purchaser acquired an additional 549,988 common shares through December 21, 2025 (previously reported).
• Further acquisitions occurred on December 22, 2025 (15,710 shares), December 23, 2025 (561,042 shares), December 24, 2025 (96,082 shares), and December 26, 2025 (142,610 shares), all at $97.00 per share.
• Following these transactions, Genmab A/S beneficially owns a total of 72,828,509 Merus N.V. common shares.

Sentiment

Score: 8

Explanation: The filing indicates the successful and ongoing execution of a strategic acquisition by Genmab, demonstrating progress towards its corporate objectives. This is a positive development for Genmab's strategic growth and for Merus shareholders who tendered their shares.

Positives

• Genmab A/S is successfully progressing with its tender offer to acquire Merus N.V., significantly increasing its beneficial ownership.
• The consistent acquisition of shares at the stated price of $97.00 indicates a clear path towards the completion of the acquisition or gaining substantial control.

Future Outlook

The ongoing acquisition of Merus N.V. by Genmab A/S through the tender offer indicates a clear strategic move towards full integration or significant control. The continued purchases in the subsequent offering period suggest Genmab is consolidating its ownership, likely leading to further steps in the acquisition process.

Management Comments

• "Parent, as the parent entity of Purchaser, beneficially owns the Common Shares held directly by Purchaser."

Industry Context

This transaction reflects a trend of consolidation within the biotechnology and pharmaceutical sectors, where larger companies acquire innovative smaller firms to expand their pipelines and market presence. Genmab's acquisition of Merus, a company focused on bispecific antibodies, aligns with strategic efforts to enhance therapeutic portfolios and leverage specialized R&D capabilities.

Related Party Transactions

• Genmab A/S (Parent) beneficially owns the common shares held directly by its wholly-owned subsidiary, Genmab Holding II B.V. (Purchaser), which is conducting the tender offer for Merus N.V. shares.

Stakeholder Impact

• Merus N.V. shareholders who tendered their shares received a cash payment of $97.00 per share.
• Genmab A/S shareholders will see the company's strategic expansion into Merus's therapeutic areas and pipeline.
• Merus N.V. as an entity is moving towards being a wholly-owned subsidiary of Genmab A/S, impacting its future operational and strategic direction.

Next Steps

• Continued acquisition of remaining outstanding common shares of Merus N.V. by Genmab Holding II B.V. during the subsequent offering period.
• Potential for further integration steps or delisting of Merus N.V. shares if ownership thresholds are met.

Key Dates

Keywords

Merus N.V., Genmab A/S, Tender Offer, Acquisition, Common Shares, Beneficial Ownership, SEC Form 4, MRUS